Citations Appearing in 2011

  1. Abdelraouf, K., S. Kabbara, K.R. Ledesma, K. Poole, and V.H. Tam. Effect of multidrug resistance-conferring mutations on the fitness and virulence of pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 66(6):1311-1317, 2011.
  2. Abraham, A., T. Maurer, A. Kalgutkar, X. Gao, M. Li, D. Healy, and D. Mager. Pharmacodynamic model of parathyroid hormone modulation by a negative allosteric modulator of the calcium-sensing receptor. The American Association of Pharmaceutical Scientists Journal 13(2):265-273, 2011.
  3. Baek, I.H., W. Kang, H.Y. Yun, S.S. Lee, and K.I. Kwon. Modelling the atypical absorption of menatetrenone and the metabolism to its epoxide: effect of VKORC1 polymorphism. Journal of Clinical Pharmacy and Therapeutics 36(3):390-398, 2011.
  4. Baxter, P., P. Thompson, L. Mcguffey, B. Gibson, R. Dauser, J. Nuchtern, and S. Blaney. Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. Cancer Chemotherapy and Pharmacology 67(4):809-812, 2011.
  5. Berger, T.W. and et al. A cortical neural prosthesis for restoring and enhancing memory. Journal of Neural Engineering 8(4): 046017, 2011.
  6. Bertrand, J., C. Laffont, F. Mentré, M. Chenel, and E. Comets. Development of a complex parent-metabolite joint population pharmacokinetic model American Association of Pharmaceutical Scientists Journal 13(3):390-404, 2011.
  7. Beumer, J., J. Eiseman, J. Gilbert, J. Holleran, A. Yellow-Duke, D. Clausen, . . .and M. Egorin. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemotherapy and Pharmacology 67(2): 421-430, 2011.
  8. Brem, E.A., K. Thudium, S. Khubchandani, P.-C. Tsai, S.H. Olejniczak, S. Bhat,…and F.J. Hernandez-llizaliturri. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology 153(5):599-611, 2011.
  9. Brown, A.N., J.B. Bulitta, J.J. McSharry, Q. Weng, J.R. Adams, R. Kulawy, and G.L. Drusano. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model Antimicrobial Agents and Chemotherapy 55(4):1747-1753, 2011.
  10. Brown, A.N., J.J. Mcsharry, Q. Weng, J.R. Adams, R. Kulawy, and G.L. Drusano. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 inluenza vrus in an in vitro hollow-fiber infection model system. Antimicrobial Agents and Chemotherapy 55(4):1740-1746, 2011.
  11. Bulitta, J., A. Bingölbali, B. Shin, and C. Landersdorfer. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. The American Association of Pharmaceutical Scientists Journal 13(2):201-211, 2011.
  12. Bulitta, J. and C. Landersdorfer. Performance and robustness of the monte carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. The American Association of Pharmaceutical Scientists Journal 13(2):212-226, 2011.
  13. Bulitta, J.B., M. Kinzig, C.B. Landersdorfer, U. Holzgrabe, U. Stephan, and F. Sorgel. Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers. Antimicrobial Agents and Chemotherapy 55(6):2927-2936, 2011.
  14. Cao, Y., D. DuBois, H. Sun, R.R. Almon, and W.J. Jusko. Modeling diabetes disease progression and salsalate intervention in goto-kakizaki rats. Journal of Pharmacology and Experimental Therapeutics 339(3):896-904, 2011.
  15. Cao, Y., W. Gao, and W. Jusko. Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats. Pharmaceutical Research 29(4):1078-1086, 2011.
  16. Cardone, K.E., T.P. Lodise, N. Patel, C.D. Hoy, S. Meola, H.J. Manley, and D.W. Grabe. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clinical Journal of the American Society of Nephrology 6(5):1081-1088, 2011.
  17. Chan, H.M., R. Jain, B. Ahrén, G. Pacini, and D.Z. D’Argenio. Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. American Journal of Physiology – Regulatory, Integrative and Comparative Physiology 300(5):R1126-R1133, 2011.
  18. Chan, P., P. Jacqmin, M. Lavielle, L. McFadyen,and B. Weatherley. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects Journal of Pharmacokinetics and Pharmacodynamics 38(1):41-61, 2011.
  19. Cha Colucci, P., J. Grenier, C.S. Yue, J. Turgeon, and M.P. Ducharme. Performance of different population pharmacokinetic algorithms. Therapeutic drug monitoring 33(5):583-591 510, 2011.
  20. Colucci, P., J. Grenier, C.S. Yue, J. Turgeon and M.P. Ducharme. Performance of Different Population Pharmacokinetic Algorithms. Therapeutic Drug Monitoring 33(5): 583-591, 2011.
  21. Darbari, D.S., M. Neely, J. Van Den Anker, and S. Rana. Increased clearance of morphine in sickle cell disease: implications for pain management. The Journal of Pain 12(5):531-538, 2011.
  22. Drusano, G.L., W. Liu, R. Kulawy, and A. Louie. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrobial Agents and Chemotherapy 55(11):5300-5305, 2011.
  23. Drusano, G.L., T.P. Lodise, D. Melnick, W. Liu, A. Oliver, A. Mena, and A. Louie. Meropenem penetration into epithelial lining fluid in mice and men and delineation of exposure targets. Antimicrobial Agents and Chemotherapy 55(7):3406-3412, 2011.
  24. Drusano, G.L. and A. Louie. Optimization of aminoglycoside therapy. Antimicrobial Agents and Chemotherapy 55(6):2528-2531, 2011.
  25. Drusano, G.L. Effect of administration of moxifloxacin plus rfampin against mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. mBio 2(4):2011.
  26. Elmeliegy, M.A., A.M. Carcaboso, M. Tagen, F. Bai, C.F. Stewart. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clinical Cancer Research 17(1):89-99, 2011.
  27. Fang, J., D. DuBois, Y. He, R. Almon, W. Jusko. Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats. Journal of Pharmacokinetics and Pharmacodynamics 38(3):293-316, 2011.
  28. Frangi, A.F., J.L. Coatrieux, G.C.Y. Peng, D.Z. D’Argenio, V.Z. Marmarelis, A. Michailova. Editorial:speciaI issue on multiscale modeling and analysis in computational biology and medicine-part-1. Biomedical Engineering, IEEE Transactions 58(10):2936-2942, 2011.
  29. Free Egelund, E., A.B. Barth, and C.A. Peloquin. Population pharmacokinetics and its role in anti-tuberculosis drug development and optimization of treatment. Current Pharmaceutical Design 17(27):2889-2899, 2011.
  30. Gao, W., S. Bihorel, D. Dubois, R. Almon, and W. Jusko. Mechanism-based disease progression modeling of type 2 diabetes in goto-kakizaki rats. Journal of Pharmacokinetics and Pharmacodynamics 38(1):143-162, 2011.
  31. Gao, W., and W.J. Jusko. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic goto-kakizaki rats. Journal of Pharmacology and Experimental Therapeutics 336(3):881-890, 2011.
  32. Garonzik, S.M., J. Li, V. Thamlikitkul, D.L. Paterson, S. Shoham,…and R.L. Nation. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrobial Agents and Chemotherapy 55(7):3284-3294, 2011.
  33. Guo, B., K. Abdelraouf, K.R. Ledesma, K.-T. Chang, M. Nikolaou, and V.H. Tam. Quantitative impact of neutrophils on bacterial clearance in a murine pneumonica model. Antimicrobial Agents and Chemotherapy 55(10):4601-4605, 2011.
  34. Hall, R.G., M.A. Swancutt, and T. Gumbo. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrobial Agents and Chemotherapy 55(11):5107-5112, 2011.
  35. Hao, K., P. Gong, S.-Q. Sun, H.-P. Hao, G.-J. Wang, Y. Dai, and H.-Y. Li. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the estrogen-like effect of ginsenoside Rb1 on neural 5-HT in ovariectomized mice. European Journal of Pharmaceutical Sciences 44(1-2):117-126, 2011.
  36. Jasinski, P., P. Zwolak, R.I. Vogel, V. Bodempudi, K. Terai, J. Galvez, and A. Dudek. MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis. Investigational New Drugs 29(5):846-852, 2011.
  37. Jasinski, P., P. Zwolak, K. Terai, R. I. Vogel, D. Borja-Cacho, and A.Z. Dudek. MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling. Anticancer Research 31(4):1181-1187, 2011.
  38. Jeena, P.M., W.R. Bishai, J.G. Pasipanodya, and T. Gumbo. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrobial Agents and Chemotherapy 55(2):539-545, 2011.
  39. Kagan, L., P. Gershkovich, K. Wasan, D. Mager. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data. The American Association of Pharmaceutical Scientists Journal 13(2):255-264, 2011.
  40. Kang, W. Myocardial pharmacokinetics of ebastine, a substrate for cytochrome P450 2J, in rat isolated heart. British Journal of Pharmacology 163(8):1733-1739, 2011.
  41. Kebriaei, P., T. Madden, R. Kazerooni, X. Wang, P.F. Thall, C. Ledesma, and B.S. Andersson. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biology of Blood and Marrow Transplantation 17(3):412-420, 2011.
  42. Knoderer, C.A., S.A. Saft, S.G. Walker, M.D. Rodefeld, M.W. Turrentine, J.W. Brown, D.P. Healy, and K.M. Sowinski. Cefuroxime pharmacokinetics in pediatric cardiovascular surgery patients undergoing cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia 25(3):425-430, 2011.
  43. Kwa, A.L.H., K. Abdelraouf, J.G.H. Low, and V.H. Tam. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clinical Infectious Diseases 52(10):1280-1281, 2011.
  44. Lin, H.-Y., C.B. Landersdorfer, D. London, R. Meng, C.-U. Lim, C. Lin, S. Lin, Sharon,…and P.J. Davis. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system PLoS Computational Biology 7(2):e1001073, 2011.
  45. Liu, D., H.-K. Lon, D. DuBois, R. Almon, W. Jusko. Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in lewis rats with collagen-induced arthritis. Journal of Pharmacokinetics and Pharmacodynamics 38(6):769-786, 2011.
  46. Lodise, T.P., F. Sorgel, D. Melnick, B. Mason, M. Kinzig, and G.L. Drusano. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrobial Agents and Chemotherapy 55(4):1606-1610, 2011.
  47. Lon, H.-K., D. Liu, Q. Zhang, D. DuBois, R. Almon, W. Jusko. Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in lewis rats with collagen-induced arthritis. Pharmaceutical Research 28(7):1622-1630, 2011.
  48. Louie, A., H.S. Heine, B. Vanscoy, A. Eichas, K. Files, S. Fikes, and G.L. Drusano. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of yersinia pestis and prevents emergence of resistance. Antimicrobial Agents and Chemotherapy 55(2):822-830, 2011.
  49. Louie, A., W. Liu, R. Kulawy, and G.L. Drusano. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant staphylococcus aureus in a mouse thigh infection model. Antimicrobial Agents and Chemotherapy 55(7):1606-1610, 2011.
  50. Marathe, D.D., A. Marathe, and D.E. Mager. Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharmaceutics and Drug Disposition 32(8):471-481, 2011.
  51. Markakis, M.G., G.D. Mitsis, G.P. Papavassilopoulos, P.A. Ioannou and V.Z. Marmarelis. A switching control strategy for the attenuation of blood glucose disturbances. Optimal Control Applications and Methods 32(2): 185-195, 2011.
  52. Mikkelsen, T.S., A. Sparreboom, C. Cheng, Y. Zhou, J.M. Boyett, S.C. Raimondi, . . .and W.E. Evans. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. Journal of Clinical Oncology 29(13):1771-1778, 2011.
  53. Moore, A.S., R. Norris, G. Price, T. Nguyen, M. Ni, R. George, and R. Pinkerton. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach. Journal of Paediatrics and Child Health 47(12):875-882, 2011.
  54. Nair Sabarinath, S., B. Wu, C. Peloquin, and H. Derendorf. Pharmacometrics in dose finding or dose optimization of anti-retroviral and anti-tubercular Drugs. Infectious Disorders – Drug Targets 11(2):157-166, 2011.
  55. Nemeth, K.M., S. Federico, A.M. Carcaboso, Y. Shen, P. Schaiquevich, J. Zhang, . . .and M.A. Dyer. Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer 117(2):421-434, 2011.
  56. Okusanya, O.O., B.T. Tsuji, J.B. Bülitta, A. Forrest, C.C. Bulik, S.M. Bhavnani, P. Fernandes, and P.G. Ambrose. Evaluation of the pharmacokinetics–pharmacodynamics of fusidic acid against staphylococcus aureus and streptococcus pyogenes using in vitro infection models: implications for dose selection Diagnostic Microbiology and Infectious Disease 70(1):101-111, 2011.
  57. Pai, M.P., and L.P. Thomas. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Antimicrobial Agents and Chemotherapy 55(12):5640-5645, 2011.
  58. Park, J.R., J.R. Scott, C.F. Stewart, W.B. London, A. Naranjo, V.M. Santana, K.K. Matthay. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a children’s oncology group study. Journal of Clinical Oncology 29(33):4351-4357, 2011.
  59. Pasipanodya, J. and T. Gumbo. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrobial Agents and Chemotherapy 55(1):24-34, 2011.
  60. Patel, N., K. Cardone, D.W. Grabe, S. Meola, C. Hoy, H. Manley, and T.P. Lodise. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrobial Agents and Chemotherapy 55(4):1677-1683, 2011.
  61. Patel, N., M.P. Pai, K.A. Rodvold, B. Lomaestro, G.L. Drusano, and T.P. Lodise. Vancomycin: we can’t get there from here. Clinical Infectious Diseases 52(8):969-974, 2011.
  62. Pietanza, M.C., S.M. Gadgeel, A. Dowlati, T.J. Lynch, R. Salgia, K.M. Rowland, Jr., . . .and N.A. Rizvi. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. Journal of Thoracic Oncology 7(5): 856-865, 2011.
  63. Prémaud, A., L.T. Weber, B. Tönshoff, V.W. Armstrong, M. Oellerich, S. Urien, A. Rousseau. Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. Pharmacological Research 63(3):216-224, 2011.
  64. Prokocimer, P., P. Bien, J. Surber, P. Mehra, C. DeAnda, J.B. Bulitta, and G.R. Corey. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrobial Agents and Chemotherapy 55(2):583-592, 2011.
  65. Saint-Marcoux, F., V. Guigonis, S. Decramer, P. Gandia, B. Ranchin, F. Parant, and P. Marquet. Development of a bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacological Research 63(5):423-431, 2011.
  66. Salem, A.H., W.F. Elkhatib, and A.M. Noreddin. Pharmacodynamic assessment of vancomycin–rifampicin combination against methicillin resistant staphylococcus aureus biofilm: a parametric response surface analysis. Journal of Pharmacy and Pharmacology 63(1):73-79, 2011.
  67. Salvatore, C.M., K. Abdelraouf, D.D. Hsing, and V.H. Tam. Pharmacokinetics of polymyxin B in an infant with multidrug-resistant klebsiella pneumoniae bacteremia. The Pediatric Infectious Disease Journal 30(6):537-539, 2011.
  68. Sangkatumvong, S., M.C.K. Khoo, R. Kato, J.A. Detterich,…and T.D. Coates. Peripheral vasoconstriction and abnormal parasympathetic response to sighs and transient hypoxia in sickle cell disease. American Journal of Respiratory and Critical Care Medicine 184(4):474-481, 2011.
  69. Serdoz, F., D. Voinovich, B. Perissutti, I. Grabnar, D. Hasa, R. Ballestrazzi, E. Coni, and E. Pellegrini. Development and pharmacokinetic evaluation of erythromycin lipidic formulations for oral administration in rainbow trout (oncorhynchus mykiss). European Journal of Pharmaceutics and Biopharmaceutics 78(3):401-407, 2011.
  70. Shah, D., and A. Betts. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Journal of Pharmacokinetics and Pharmacodynamics 39(1):67-86, 2011.
  71. Shin, B.S., J.B. Bulitta, D.K. Hong, H.Y. Kim, M.K. Kim, Y. Choi, J.B. Lee,…and S.D. Yoo. Population pharmacokinetics of a novel histone deacetylase inhibitor, cyclo{(2S)-2-amino-8-[(aminocarbonyl)hydrazono] decanoyl-1-L-tryptophyl-l-isoleucyl-(2R)-2-piperidinecarbonyl} (SD-2007), and Its metabolic conversion to apicidin after intravenous injection and oral administration in rats Chemotherapy 57(3):259-267, 2011.
  72. Slater, J.L., S.J. Howard, A. Sharp, J. Goodwin, L.M. Gregson, A. Alastruey-Izquierdo,…and W.W. Hope. Disseminated candidiasis caused by candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrobial Agents and Chemotherapy 55(7):3075-3083, 2011.
  73. Song, J.S., J.-W. Chae, K.-R. Lee, B.H. Lee, E.J. Choi, S.H. Ahn, and M. A. Bae. Pharmacokinetic characterization of decursinol derived from angelica gigas nakai in rats. Xenobiotica 41(10):895-902, 2011.
  74. Song, J.S., H.J. Rho, J.S. Park, M.S. Kim, B.H. Lee, J.-W. Seo, and M.A. Bae. Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor. Drug Metabolism and Pharmacokinetics 26(2):192-200, 2011.
  75. Soto, E., A. Staab, C. Doege, M. Freiwald, G. Munzert, and I. Trocóniz. Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor. Cancer Chemotherapy and Pharmacology 68(6):1517-1527, 2011.
  76. Srivastava, S., J. Pasipanodya, C. Meek, R. Leff, and T. Gumbo. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. Journal of Infectious Diseases 204(12):1951-1959, 2011.
  77. Srivastava, S., C. Sherman, C. Meek, R. Leff, and T. Gumbo. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrobial Agents and Chemotherapy 55(11):5085-5089, 2011.
  78. Sukumaran, S., W.J. Jusko, D.C. DuBois, and R.R. Almon. Mechanistic modeling of the effects of glucocorticoids and circadian rhythms on adipokine expression. Journal of Pharmacology and Experimental Therapeutics 337(3):734-746, 2011.
  79. Sutcliffe, J.A. Antibiotics in development targeting protein synthesis. Annals of the New York Academy of Science 1241(1):122-152, 2011.
  80. Tam, V.H. and M. Nikolaou. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. Public Library of Science Computational Biology 7(1):e1001043, 2011.
  81. Tod, M., O. Mir, N. Bancelin, R. Coriat, A. Thomas-Schoemann, F. Taieb, and B. Blanchet. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharmaceutical Research 28(12):3199-3207, 2011.
  82. Tönshoff, B., E. David-Neto, R. Ettenger, G. Filler, T.V. Gelder, J. Goebel,…and L.B. Zimmerhackl. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplantation Reviews 25(2):78-89, 2011.
  83. Troke, P.F., H.P. Hockey, and W.W. Hope. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrobial Agents and Chemotherapy 55(10):4782-4788, 2011.
  84. Vilay, A.M., M. Grio, D.D. DePestel, K. Sowinski, L. Gao, M. Heung, N.N. Salama, and B.A. Mueller. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Critical Care Medicine 39(1):19-25, 2011.
  85. Webster, L.R., F.K. Johnson, J. Stauffer, B. Setnik, and S. Ciric. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs in R&D 11(3):259-275, 2011.
  86. Weiss, M., T.C. Krejcie, M.J. Avram. A physiologically based model of hepatic ICG clearance: interplay between sinusoidal uptake and biliary excretion. European Journal of Pharmaceutical Sciences: 44(3):359-365, 2011.
  87. Weiss, M., M. Reekers, J. Vuyk, F. Boer. Circulatory model of vascular and interstitial distribution kinetics of rocuronium: a population analysis in patients. Journal of Pharmacokinetics and Pharmacodynamics 38(2):165-178, 2011.
  88. Wenisch, J.M., B. Meyer, V. Fuhrmann, K. Saria, C. Zuba, P. Dittric, and F. Thalhammer. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy 67(7):1-7, 2011.
  89. Wittau, M., J. Scheele, J.B. Bulitta, B. Mayer, V. Kaever, H. Burhenne, D. Henne-Bruns, and C. Brockschmidt. Pharmacokinetics of ertapenem in colorectal tissue Chemotherapy 57(5):437-448, 2011.
  90. Woillard, J.-B., B.C.M. de Winter, N. Kamar, P. Marquet, L. Rostaing, and A. Rousseau. Population pharmacokinetic model and bayesian estimator for two tacrolimus formulations – twice daily Prograf® and once daily Advagraf®. British Journal of Clinical Pharmacology 71(3):391-402, 2011.
  91. Wong, H., B. Alicke, K.A. West, P. Pacheco, H. La, T. Januario, and S.E. Gould. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation. Clinical Cancer Research 17(14):4682-4692, 2011.
  92. Wu, B. and M. Hu. A useful microsoft excel add-in program for pharmacokinetic analysis. Pharmaceutica Analytica Acta S11:1-7, 2011.
  93. Xia, X., Y. Pan, Z. Ou-Yang, J. Wang, L.-L. Pan, Q. Zhu, and L.-D. Kong. Pharmacokinetic-pharmacodynamic modeling of monoamine oxidase a inhibitory activity and bhavior improvement by curcumin in the mouse forced swimming test. Chinese Journal of Natural Medicines 9(4):293-304, 2011.
  94. Zamboni, W.C., J.L. Eiseman, S. Strychor, P.M. Rice, E. Joseph, B.A. Zamboni,…and P.H. Basse. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. Journal of Liposome Research 21(1):70-80, 2011.
  95. Zhang, F., S.L. Throm, L.L. Murley, L.A. Miller, D.S. Jr. Zatechka, R.G. Kiplin, R. Kennedy, and C.F. Stewart. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochemical Pharmacology 82(1):24-34, 2011.
  96. Zheng, Y., H. Scheerens, J.C. Davis, R. Deng, S.K. Fischer, C. Woods, . . . E.G. Stefanich. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clinical Pharmacology and Therapeutics 89(2):283-290, 2011.